

Update: New Science Advisor and Comptroller Appointment to Abattis

Vancouver, BC – September 27, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTF) (CSE: ATT) is pleased to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Dr. Xie graduated from Zhejiang University in 1987 and Queen's University in 1993. Dr. Xie has been widely published and holds more than 20 patents. She has assisted companies globally in assessing project risk, securing financing, and has undertaken numerous project management mandates. Dr. Xie is a founding partner of privately-held Efilcon Corp., a leading developer and producer of extraction technologies and systems and has assisted a number of manufacturers to carry out project assessment, financing, extraction equipment set up, and extraction plant construction. She is currently appointed as overseas talent for the Chinese government and an expert consultant for Zhejiang University Innovation Research Institute.

"We are delighted that Dr. Xie has joined Abattis. Her contribution to our new strategy is already being felt," commented acting CEO Rene David." Dr. Xie's breadth of experience and depth of knowledge in extraction technologies and systems is truly remarkable. We look forward to working with Dr. Xie."

The Company also would like to express its deep appreciation for the contributions of outgoing directors Dr. Brazos Minshew and Maryam Shanjani.

Dr. Minshew has been a member of the Board of Directors and served as Abattis' Chief Science Officer since July, 2014] during which time his efforts resulted in the development of many of its current formulations, including *PhytoNOS*, which is based on the health properties of nitric oxide. "Brazos has been a great friend and colleague to all of us here at Abattis. We wish him great success in his current endeavours," remarked fellow director Jim Irving.

Maryam Shanjani served as Controller since March 2015 during which time she contributed immensely to restructuring and recapitalization efforts undertaken by management, enabling the Company to undertake its current growth strategy. "Maryam has been a valuable member of our management team. We appreciated her commitment and valuable contributions during the past year," added acting CEO Rene David on behalf of the management team.

In her place, Abattis has engaged, Mr. Chris Cherry as its new corporate comptroller. Mr. Cherry has over 14 years of corporate accounting and audit experience. Mr. Cherry has extensive corporate experience and has held senior level positions for several public mining companies including Director, Chief Financial Officer, and Secretary. Mr. Cherry has been a Chartered Accountant since February 2009 and a Certified General Accountant since 2004. In his former experience as an auditor, he held positions with KPMG and Davidson and Co. LLP in Vancouver, where he gained experience as an auditor for junior public companies, and an IPO specialist.

We wish to welcome Mr. Cherry to our management team at Abattis during this important juncture of our company's history. The management of processes and maintaining a cost-effective program while we streamline our core activities will be Mr. Cherry's prime objectives.

We also wish to announce that we have moved our corporate headquarters to our administrative offices in Langley, BC. This will put our key resources under one roof while we patiently wait for the approvals of the Northern Vine Laboratories Medical Marijuana Testing Lab, which underwent final inspection in the early summer this year. All deficiencies were completed and we hope to see Northern Vine Labs as one of the only approved labs in BC shortly.

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company also is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Rene David"

Rene David, Acting CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.